Protein kinase C and the cytoskeleton
Rybelsus isnt licensed for weight loss in the UK
10.1007/s00125-021-05590-5 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, renal outcome, combination therapy, preceding drug, diabetic kidney disease Citation Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y and Kawanami D (2024) Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
Eastern time